Stryker Corp (SYK)

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Ticker
SYK
Exchange
NYSE
Sector
Healthcare
Industry
Medical Devices
Market cap
$120.88B
52-week range
$267.00 - $389.33

Valuation

Share price
$318.12 (close of Nov 18, 2026)
P/E (TTM)
33.60x
Price to book
5.15x
Price to free cash flow
26.43x
Enterprise value
$132.54B
Book value per share
$61.62

Price performance

PeriodChange
1 day+0.18%
5 days-0.21%
1 month+7.96%
3 months-4.00%
6 months+1.56%
Year to date-9.49%
1 year-11.52%
3 years+10.32%
5 years+22.49%
10 years+185.46%
All time+329,725.52%

Short interest

As of
Oct 30, 2026
Short % of float
1.83%
Shares short
6.66M
Days to cover
2.23
Change since prior report
+16.84%
Source
FINRA consolidated short interest

Members of Congress who disclosed SYK trades

Thomas Kean · Gilbert Ray Cisneros · Jared Moskowitz · Jefferson Shreve · Julia Letlow · Robert Bresnahan · Alan Armstrong · Julie Johnson

Super investors holding SYK

Terry Smith (Fundsmith LLP) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · Mairs & Power (Mairs & Power Inc)

Profitability and growth

Return on equity
14.48%
Return on invested capital
9.46%
Return on assets
6.78%
Return on capital employed
12.21%
Gross margin
63.96%
Net margin
12.92%
EBITDA margin
25.72%
Revenue growth
11.16%
Net income growth
8.45%
Free cash flow growth
22.83%

Cash flow and balance sheet

Free cash flow yield (TTM)
3.78%
Current ratio
2.18x
Net debt to EBITDA
1.68x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$25.12B
Cost of revenue
$9.05B
Gross profit
$16.07B
EBITDA
$6.46B
Net income
$3.25B
Earnings per share
$8.49
Research and development
$1.62B
Interest expense
$607.00M
Shares outstanding
382.20M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$25.12B$16.07B$3.25B$8.49
2024-12-31$22.59B$14.44B$2.99B$7.86
2023-12-31$20.50B$13.06B$3.17B$8.34
2022-12-31$18.45B$11.58B$2.36B$6.23
2021-12-31$17.11B$10.97B$1.99B$5.29
2020-12-31$14.35B$9.06B$1.60B$4.26
2019-12-31$14.88B$9.70B$2.08B$5.57
2018-12-31$13.60B$8.94B$3.55B$9.50
2017-12-31$12.44B$8.18B$1.02B$2.73
2016-12-31$11.32B$7.50B$1.65B$4.40

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3163.96%12.92%14.48%9.46%
2024-12-3163.91%13.25%14.51%9.32%
2023-12-3163.70%15.44%17.02%10.70%
2022-12-3162.76%12.78%14.19%8.48%
2021-12-3164.11%11.66%13.40%8.27%
2020-12-3163.11%11.14%12.22%6.79%
2019-12-3165.14%13.99%16.26%9.20%
2018-12-3165.72%26.12%30.29%11.75%
2017-12-3165.73%8.20%10.22%7.29%
2016-12-3166.26%14.54%17.25%11.55%

Cash and debt by year

Period endCashDebt
2025-12-31$4.10B$14.86B
2024-12-31$3.74B$12.19B
2023-12-31$3.05B$10.90B
2022-12-31$1.93B$11.86B
2021-12-31$3.02B$12.47B
2020-12-31$3.02B$13.23B
2019-12-31$4.42B$10.23B
2018-12-31$3.70B$8.49B
2017-12-31$2.79B$6.59B
2016-12-31$3.38B$6.69B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$4.28B$243.00M
2024-12-31$3.49B$229.00M
2023-12-31$3.14B$205.00M
2022-12-31$2.04B$168.00M
2021-12-31$2.74B$171.00M
2020-12-31$2.79B$142.00M
2019-12-31$1.54B$127.00M
2018-12-31$2.04B$119.00M
2017-12-31$961.00M$113.00M
2016-12-31$1.43B$97.00M

Dividend history

Most recent payment
Sep 30, 2026
Paid in the last twelve months
$3.52
Payment dateDividend per share
2026-09-30$0.88
2026-06-30$0.88
2026-03-31$0.88
2025-12-31$0.88
2025-09-30$0.84
2025-06-30$0.84
2025-03-31$0.84
2024-12-31$0.84

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-29Sep 2026$3.56
2026-07-30Jun 2026$3.46
2026-04-30Mar 2026$2.98
2026-01-29Dec 2025$4.40
2025-10-30Sep 2025$3.14
2025-07-31Jun 2025$3.06
2025-05-01Mar 2025$2.73
2025-01-28Dec 2024$3.87

Filings and sources

Company website
stryker.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Boston Scientific Corp (BSX) · Medtronic plc (MDT) · Edwards Lifesciences Corp (EW) · Abbott Laboratories (ABT) · GE HealthCare Technologies Inc. (GEHC) · Dexcom Inc (DXCM) · STERIS plc (STE) · Zimmer Biomet Holdings, Inc. (ZBH)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades